Literature DB >> 16518086

[Effects of silodosin (KMD-3213) on phenylephrine-induced increase in intraurethral pressure and blood pressure in rats--study of the selectivity for lower urinary tract].

Satoshi Tatemichi1, Kumi Kobayashi, Itaru Maruyama, Mamoru Kobayashi, Yoshinobu Yamazaki, Nobuo Shibata.   

Abstract

The effects of silodosin, an alpha(1A)-adrenoceptor (AR) antagonist, and of other alpha(1)-AR antagonists on the phenylephrine (PE)-induced increase in intraurethral pressure (IUP) and on blood pressure (BP) were studied in anesthetized rats. The drugs were administered intravenously (i.v. study) or intraduodenally (i.d. study). IUP and BP were measured via catheters inserted into the prostatic urethra and common carotid artery, respectively. In the i.v. study, drugs were administered every 30 min for effects on BP, and 5 min before each PE-injection (30 microg/kg, every 60 min) with stepwise increases in dose for effects on IUP. In the i.d. study, one dose of drug was administered per rat, then IUP and BP were observed for 4 h [IUP being measured time-dependently following PE-injection (30 microg/kg)], and IUP and BP were expressed as a percentage of the values without any drugs. ID(50) for IUP and ED(15) for BP were calculated, and uroselectivity was determined as ED(15)/ID(50) for each drug. All drugs both inhibited the IUP increase and lowered BP, each effect being dose-dependent. The order of uroselectivities was silodosin (11.7)>tamuslosin (2.24)>naftopidil (0.133) in the i.v. study, and silodosin (26.0)>tamuslosin (3.82)>naftopidil (1.39) in the i.d. study. Selectivity for the lower urinary tract (LUT) was higher for silodosin than for tamsulosin (alpha(1A)/alpha(1D)-AR), naftopidil (alpha(1D)-AR), or prazosin (non-selective alpha(1)-AR). These results suggested that an alpha(1A)-AR selective antagonist like silodosin might be effective in the LUT without causing hypotension.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16518086     DOI: 10.1248/yakushi.126.217

Source DB:  PubMed          Journal:  Yakugaku Zasshi        ISSN: 0031-6903            Impact factor:   0.302


  3 in total

Review 1.  Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia.

Authors:  Masaki Yoshida; Junzo Kudoh; Yukio Homma; Kazuki Kawabe
Journal:  Clin Interv Aging       Date:  2011-06-22       Impact factor: 4.458

Review 2.  Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability.

Authors:  Hee Ju Cho; Tag Keun Yoo
Journal:  Res Rep Urol       Date:  2014-09-26

Review 3.  Evolving Role of Silodosin for the Treatment of Urological Disorders - A Narrative Review.

Authors:  Luo Jindan; Wang Xiao; Xie Liping
Journal:  Drug Des Devel Ther       Date:  2022-08-26       Impact factor: 4.319

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.